deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03230292

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Sponsor: UCB Biopharma SRL

Conditions Chronic Plaque Psoriasis
Interventions Bimekizumab
Updated 17 times since 2017 Last updated: Jul 15, 2022 Started: Jul 3, 2017 Primary completion: Mar 6, 2019 Completion: Mar 6, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Plaque Psoriasis and is currently completed. UCB Biopharma SRL leads this study, which shows 17 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  3. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE2

  4. Apr 2020 — Aug 2020 [monthly]

    Completed PHASE2

  5. Oct 2019 — Apr 2020 [monthly]

    Completed PHASE2

  6. May 2019 — Oct 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  7. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Sep 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  12. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations